Lee's Pharmaceutical Holdings Ltd. (950) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Lee's Pharmaceutical Holdings Ltd.

Dawnrays Pharmaceutical Holdings Ltd.

TOT BIOPHARM International Co. Ltd.

Shanghai Henlius Biotech, Inc.

Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

Charmacy Pharmaceutical Co., Ltd.

Antengene Corp. Ltd.

Clover Biopharmaceuticals Ltd.

Shanghai Fudan Zhangjiang Bio Pharmaceutical Co., Ltd.

Transcenta Holding Ltd.

Fusen Pharmaceutical Co., Ltd.

Why is Lee's Pharmaceutical Holdings Ltd. ?

High Management Efficiency with a high ROE of 16.32%

Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 74.18

With ROE of 12.57%, it has a Very Attractive valuation with a 0.42 Price to Book Value

Over the past year, while the stock has generated a return of -24.83%, its profits have risen by 6.8% ; the PEG ratio of the company is 0.5
At the current price, the company has a high dividend yield of 335.7

Real-Time Research Report

Verdict Report

How much should you buy?

Overall Portfolio exposure to Lee's Pharmaceutical Holdings Ltd. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Lee's Pharmaceutical Holdings Ltd. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Lee's Pharmaceutical Holdings Ltd.

-24.83%

-0.18

60.41%

Hang Seng Hong Kong

8.76%

0.45

19.63%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

13.55%

EBIT Growth (5y)

13.25%

EBIT to Interest (avg)

74.18

Debt to EBITDA (avg)

Net Debt to Equity (avg)

Sales to Capital Employed (avg)

0.44

Tax Ratio

21.23%

Dividend Payout Ratio

28.83%

Pledged Shares

Institutional Holding

0.03%

ROCE (avg)

26.07%

ROE (avg)

16.32%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

0.42

EV to EBIT

3.35

EV to EBITDA

3.14

EV to Capital Employed

0.40

EV to Sales

0.75

PEG Ratio

0.51

Dividend Yield

335.71%

ROCE (Latest)

12.09%

ROE (Latest)

12.57%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bearish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

5What is working for the Company

OPERATING CASH FLOW(Y)

Highest at HKD 577.58 MM

RAW MATERIAL COST(Y)

Fallen by -1.05% (YoY

CASH AND EQV(HY)

Highest at HKD 349.9 MM

-3What is not working for the Company

DEBTORS TURNOVER RATIO(HY)

Lowest at 5.48 times

DIVIDEND PER SHARE(HY)

Lowest at HKD 5.48

PRE-TAX PROFIT(Q)

Fallen at -63.91%

Here's what is working for Lee's Pharmaceutical Holdings Ltd.

Operating Cash Flow

Highest at HKD 577.58 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (HKD MM)

Cash and Eqv

Highest at HKD 349.9 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Raw Material Cost

Fallen by -1.05% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Depreciation

Highest at HKD 83.5 MM

in the last five periods

MOJO Watch

The expenditure on assets done by the company may have gone into operation

Depreciation (HKD MM)

Depreciation

At HKD 83.5 MM has Grown at 15.73%

period on period (QoQ)

MOJO Watch

The expenditure on assets done by the company has gone into productive use which should positively reflect in the future sales

Depreciation (HKD MM)

Here's what is not working for Lee's Pharmaceutical Holdings Ltd.

Pre-Tax Profit

Fallen at -63.91%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (HKD MM)

Debtors Turnover Ratio

Lowest at 5.48 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio

Dividend per share

Lowest at HKD 5.48

in the last five years

MOJO Watch

Company is distributing lower dividend than previous years

DPS (HKD)